Avoid burning bridges before CAR-T therapy in myeloma

Avoid burning bridges before CAR-T therapy in myeloma

Saved in:

Bibliographic Details
Main Authors:	Swetha Reddi, Rahul Banerjee
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Series:	Blood Advances
Online Access:	http://www.sciencedirect.com/science/article/pii/S2473952925003040
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma
by: Rahul Banerjee, et al.
Published: (2025-06-01)

Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma
by: Jan H. Frenking, et al.
Published: (2025-08-01)

BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma
by: Chengwei Jin, et al.
Published: (2025-12-01)

After CAR-T therapy for myeloma: challenge of persistent cytopenias and infections
by: Ofrat Beyar-Katz, et al.
Published: (2025-08-01)

CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
by: Tong Yu, et al.
Published: (2025-02-01)

Maximizing the Benefit of CAR T-Cell Therapy in Lymphoma and Multiple Myeloma
by: Federico Simonetta
Published: (2022-10-01)

REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY
by: Ulrike Bacher, et al.
Published: (2021-01-01)

Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma
by: Andrew J. Portuguese, et al.
Published: (2025-06-01)

Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma
by: Tyra K. Grischke, et al.
Published: (2025-03-01)

BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement
by: Mahmoud R. Gaballa, et al.
Published: (2025-03-01)

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
by: Patrick Born, et al.
Published: (2025-06-01)

Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma
by: Brandon Tedder, et al.
Published: (2025-07-01)

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
by: Rahul Banerjee, et al.
Published: (2025-05-01)

Case Report: Summary of multiple CAR-T expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for multiple myeloma
by: Liya Wei, et al.
Published: (2025-06-01)

Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
by: Faroogh Marofi, et al.
Published: (2021-03-01)

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy
by: Lingling Yin, et al.
Published: (2025-04-01)

Serum ferritin as a prognostic biomarker in CAR-T therapy for multiple myeloma: A meta-analysis
by: Jing Cheng, et al.
Published: (2025-03-01)

Pre-infusion ferritin a predictive biomarker for CAR T-cell therapy in R/R multiple myeloma
by: Eider F. Moreno-Cortes, et al.
Published: (2025-08-01)

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
by: Yuhan Yan, et al.
Published: (2024-11-01)

Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
by: Yok-Lam Kwong, et al.
Published: (2025-03-01)

Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma
by: Ning An, et al.
Published: (2025-05-01)

Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma
by: Johannes M. Waldschmidt, et al.
Published: (2025-03-01)

Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy
by: Jessica S. Little, et al.
Published: (2025-08-01)

Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting
by: Yuhan Hu, et al.
Published: (2025-03-01)

Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma
by: Joshua N. Gustine, et al.
Published: (2025-06-01)

Editorial Expression of Concern: Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
by: Stem Cell Research & Therapy Editorial Board
Published: (2025-04-01)

Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival
by: Zachary M. Avigan, et al.
Published: (2025-01-01)

Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
by: Yannis K. Valtis, et al.
Published: (2025-01-01)

From Multi‐Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR‐T Cell Therapy
by: Yuting Gong, et al.
Published: (2025-05-01)

Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma
by: Lili Zhou, et al.
Published: (2025-05-01)

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2024-10-01)

CHARACTERISTICS OF BONE MARROW MICROENVIRONMENT IN MULTIPLE MYELOMA BEFORE AND AFTER TREATMENT
by: V. I. Rugal, et al.
Published: (2019-03-01)

The management of multiple myeloma patients accompanied with disseminated intravascular coagulation before receiving LCAR-B38M therapy
by: Ruijun Dong, et al.
Published: (2025-04-01)

Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review
by: Satchie Sakamoto, et al.
Published: (2024-01-01)

SBRT for bridging and downstaging HCC before transplant
by: Zhihao Li, et al.
Published: (2025-08-01)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
by: S. A. Tuchman, et al.
Published: (2012-01-01)

PROBLEMS OF BURNING CONTROL IN FLAME FURNACES FOR HEATING OF SLUGS BEFORE PUNCHING
by: A. A. Oznobishin
Published: (2011-02-01)

THE SYSTEM OF AUTOMATED AVOIDANCE OF HAZARDOUS SITUATIONS AT AIRCRAFT APPROACH BEFORE GLIDESLOPE DESCENT
by: A. I. Eremin, et al.
Published: (2016-11-01)

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation
by: Thomas Kimman, et al.
Published: (2025-05-01)

Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma
by: Roman Galetto, et al.
Published: (2024-07-01)